<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01071460</url>
  </required_header>
  <id_info>
    <org_study_id>Prov 01-2009</org_study_id>
    <secondary_id>147-2009-06072009</secondary_id>
    <nct_id>NCT01071460</nct_id>
  </id_info>
  <brief_title>Evaluation of Efficacy and Safety of the FlexStent Self-Expanding Stent System</brief_title>
  <official_title>The FlexStent-Registry, Evaluation of Efficacy and Safety of the FlexStent Femoropopliteal Self-Expanding Stent System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Provascular GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Provascular GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose of this registry is to determine the efficacy and safety of the self-expanding, extra&#xD;
      flexible FlexStent in patient with superficial femor/popliteal artery disease.&#xD;
&#xD;
      The stent has been developed to cope with the extreme requirements of the femoral artery/knee&#xD;
      artery and is approved for usage at humans (EC-certified). It is designed to treat narrows of&#xD;
      the femoral- and knee artery.&#xD;
&#xD;
      100 patients at 5 German hospital shall be enrolled. After stent implantation follow-up&#xD;
      visits at 6 and 12 month take place.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Peripheral arterial disease (PAD) represents a major challenge to physicians in treating the&#xD;
      Superficial Femoral (SFA) and Popliteal arteries. These arteries represent a harsh&#xD;
      environment for any endovascular device. This disease is characterized by long occlusions&#xD;
      with relatively low flow and with the vessels exposed to enormous mechanical stress. During&#xD;
      flexing of the knee, the SFA/Popliteal arteries can bend, rotate, elongate and compress&#xD;
      dramatically. An ideal stent designed for use in the SFA/Popliteal arteries would offer great&#xD;
      ranges of movement while adequately supporting the arteries.&#xD;
&#xD;
      The FlexStent® stent provides a great range of motions for a highly flexible femoral artery&#xD;
      while adequately supporting the vessel. The intended use for the FlexStent® stent is for the&#xD;
      treatment of symptomatic femoropopliteal disease, primarily for atherosclerotic de novo&#xD;
      native superficial femoral artery lesions.&#xD;
&#xD;
      The intent of this clinical registry is to demonstrate the efficacy and safety of the&#xD;
      FlexStent® stent in patients with superficial femoral/ popliteal artery disease.&#xD;
&#xD;
      Hypothesis: the FlexStent® will be safe and efficacious in treating SFA/popliteal artery&#xD;
      diseases.&#xD;
&#xD;
      Primary object: evaluation of efficacy of the FlexStent® measured by the in-stent restenosis&#xD;
      using DUS following treatment, 6 and 12 MFU visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>in-stent binary restenosis using DUS</measure>
    <time_frame>after treatment, at 6 and 12 MFU</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>technical success, defined as the ability to implant the stent with a residual angiographic stenosis no greater than 30%</measure>
    <time_frame>at 6 and 12 MFU</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Efficacy of the Study Device</condition>
  <arm_group>
    <arm_group_label>SFA Stenting</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FlexStent Femoropopliteal Self-Expanding Stent System</intervention_name>
    <description>Peri-procedural management will be no different to routine SFA/Popliteal Artery intervention Standard medical therapy&#xD;
Procedural techniques will be identical to routine protocols for SFA/Popliteal Artery stenting. technique suggested:&#xD;
Contralateral retrograde common femoral cross-over access or antegrade access&#xD;
Target lower limb arteries fully imaged angiogram. with measurement of SFA/Popliteal Artery target lesion length and normal vessel diameter immediately above and below target lesion&#xD;
Pre-stenting balloon dilatation of target lesion in all total occlusions and critical stenosis&#xD;
Deployment of an appropriately sized FlexStent® to cover target lesion&#xD;
Post-stent balloon dilate stent using a semi-compliant angioplasty balloon to enable accurate post-dilatation of stent to target diameter&#xD;
Post stenting angiography assessing target lesion parameters, run-off vessel patency and complications</description>
    <arm_group_label>SFA Stenting</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects, male or female, must be between the ages of 35 to 85 years inclusive at the&#xD;
             time of consent. A female of childbearing potential may be enrolled, provided she has&#xD;
             a negative pregnancy test at Screening.&#xD;
&#xD;
          -  Subjects must give written informed consent prior to participation in the study and&#xD;
             must understand the purpose of this study and be willing to adhere to the study&#xD;
             procedures described in this protocol.&#xD;
&#xD;
          -  Rutherford Classification Category 2-4&#xD;
&#xD;
          -  Single de novo lesion in the superficial femoro/popliteal artery&#xD;
&#xD;
          -  Disease segment length ≤150mm&#xD;
&#xD;
             -&gt;70% diameter stenosis and occlusion&#xD;
&#xD;
          -  Patent ipsilateral iliac artery&#xD;
&#xD;
          -  Patent ipsilateral popliteal artery and at least 1 patent tibial artery in continuity&#xD;
             to ankle&#xD;
&#xD;
          -  Target reference vessel diameter 3.5-7.5 mm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Target lesion previously treated with a stent or surgery.&#xD;
&#xD;
          -  Rutherford Classification Category 0,1,5 or 6.&#xD;
&#xD;
          -  Inability to tolerate antithrombotic or antiplatelet therapies.&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Other comorbidity risks which in the opinion of the investigator limit longevity or&#xD;
             likelihood of complying with protocol follow up.&#xD;
&#xD;
          -  Serum creatinine &gt; 2.5 mg/dL.&#xD;
&#xD;
          -  Myocardial infarction or stroke within 90 days of enrollment.&#xD;
&#xD;
          -  Hypercoagulable state.&#xD;
&#xD;
          -  Uncontrollable hypertension.&#xD;
&#xD;
          -  Patients currently enrolled in any other clinical trial(s).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dierk Scheinert, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Park-Krankenhaus Leipzig</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herz-Zentrum Bad Krozingen Abteilung Angiologie</name>
      <address>
        <city>Bad Krozingen</city>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jüdisches Krankenhaus Berlin, Gefäßzentrum</name>
      <address>
        <city>Berlin</city>
        <zip>13347</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Park-Krankenhaus Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <study_first_submitted>February 18, 2010</study_first_submitted>
  <study_first_submitted_qc>February 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2010</study_first_posted>
  <last_update_submitted>November 8, 2012</last_update_submitted>
  <last_update_submitted_qc>November 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2012</last_update_posted>
  <responsible_party>
    <name_title>Dierk Scheinert, MD</name_title>
    <organization>Park Krankenhaus Leipzig</organization>
  </responsible_party>
  <keyword>PAD</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

